Superworth

Larimar Therapeutics EPS LRMR

Diluted earnings per share by quarter and over the last twelve months, from 2013.

Last 12 months, to Sep 30, 2025
−$1.93
Latest quarter, Q3 FY25
−$0.61
Fiscal year 2024
−$1.30

Larimar Therapeutics' earnings per share was −$1.93 over the twelve months to Sep 30, 2025.

In its latest quarter, Q3 FY25, it was −$0.61.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2024−$1.30n/a
FY2023−$0.85n/a
FY2022−$1.54n/a
FY2021−$2.97n/a
FY2020−$3.84n/a
FY2019−$8.51n/a
FY2018−$23.40n/a
FY2017−$22.92n/a
FY2016−$25.44n/a
FY2015−$33.24n/a
FY2014−$123.24n/a
FY2013−$234.48n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY25−$0.61n/a−$1.93
Q2 FY25−$0.41n/a−$1.56
Q1 FY25−$0.46n/a−$1.49
Q4 FY24−$0.45n/a−$1.30
Q3 FY24−$0.24n/a−$1.15
Q2 FY24−$0.34n/a−$1.12
Q1 FY24−$0.27n/a−$0.97
Q4 FY23−$0.30n/a−$0.85
Q3 FY23−$0.21n/a−$0.76
Q2 FY23−$0.19n/a−$0.92
Q1 FY23−$0.15n/a−$1.20
Q4 FY22−$0.21n/a−$1.54

Against its peers

Companies in Drug Manufacturers - General nearest Larimar Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
LRMRLarimar Therapeuticsn/m
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
LFVNLifevantage$0.40−46% a year
ABUSArbutus Biopharma$0.78
SPROSpero Therapeutics$0.11
Peer median$0.78

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Larimar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.